An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone ...

Circadian rhythms are endogenous oscillations widely present in living organisms, typically following approximately 24-hour ...

Roche’s long-stuttering attempt to bring the cancer drug candidate ipatasertib to market has run out of steam. After multiple clinical setbacks, the Swiss pharma giant has dropped (PDF) a phase 3 ...

Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds ...